Sumitomo Pharma Sets Terms for Over ¥100 Billion Equity Offering

Sumitomo Dainippon Pharma Co ( (JP:4506) ) has shared an update.

Sumitomo Pharma Co., Ltd. has set the terms for a major equity financing, determining the issue and selling prices for a public offering of 51,304,400 new common shares at 1,990 yen per share, raising just over 102 billion yen in gross proceeds. The transaction, split between Japanese and international underwriters, will significantly bolster the company’s capital base by increasing both capital stock and capital surplus, supporting its financial flexibility and potential investment capacity.

In addition to the main public offering, the company will conduct a secondary offering of 7,695,600 shares via over-allotment and a third-party allotment of up to the same number of new shares, also priced off the determined terms. These additional structures are designed to stabilize the share offering and provide further capital of up to roughly 14.7 billion yen, which may affect existing shareholders through dilution while strengthening the company’s balance sheet and funding options.

The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2700.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.

More about Sumitomo Dainippon Pharma Co

Sumitomo Pharma Co., Ltd., based in Osaka, Japan, is a pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange. The company develops and sells prescription drugs and related healthcare products, focusing on domestic and international markets through both Japanese and international underwriting channels.

YTD Price Performance: -5.44%

Average Trading Volume: 12,170,176

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen870.9B

For detailed information about 4506 stock, go to TipRanks’ Stock Analysis page.